Rett Syndrome pre-IND meeting held with FDA
Filed with ASX ·
6ix hasn’t read this filing yet.
Neuren Pharmaceuticals Limited on 6ix
Earlier from Neuren Pharmaceuticals
- Appendix 4E and Financial Report 31 December 2015
- Trofinetide successful in Phase 2 trial in Fragile X
- US$3m increase to US Army grant and INTREPID outlook update
- Share Purchase Plan offer documents
- Shareholder Update
Later from Neuren Pharmaceuticals
- NEU: Neuren places $3m of rights issue shortfall
- Neuren Rights Issue Letter of Offer (Australian residents)
- Neuren Rights Issue Offer Document (NZ residents)
- Neuren Completes Phase II trial Cohort 1
- Neuren reduces outstanding convertible note principal
Follow Neuren Pharmaceuticals into a list and get an email when it puts out news.
Follow Neuren Pharmaceuticals